1. Academic Validation
  2. FBXO42 facilitates Notch signaling activation and global chromatin relaxation by promoting K63-linked polyubiquitination of RBPJ

FBXO42 facilitates Notch signaling activation and global chromatin relaxation by promoting K63-linked polyubiquitination of RBPJ

  • Sci Adv. 2022 Sep 23;8(38):eabq4831. doi: 10.1126/sciadv.abq4831.
Hua Jiang 1 2 3 Weixiang Bian 1 2 3 Yue Sui 1 2 3 Huanle Li 2 3 Han Zhao 2 3 Wenqi Wang 4 Xu Li 1 2 3
Affiliations

Affiliations

  • 1 Fudan University, Shanghai 310018, China.
  • 2 Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang, China.
  • 3 Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, Zhejiang, China.
  • 4 Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA 92697, USA.
Abstract

Dysregulation of the Notch-RBPJ (recombination signal-binding protein of immunoglobulin kappa J region) signaling pathway has been found associated with various human diseases including cancers; however, precisely how this key signaling pathway is fine-tuned via its interactors and modifications is still largely unknown. In this study, using a proteomic approach, we identified F-box only protein 42 (FBXO42) as a previously unidentified RBPJ interactor. FBXO42 promotes RBPJ polyubiquitination on lysine-175 via lysine-63 linkage, which enhances the association of RBPJ with chromatin remodeling complexes and induces a global chromatin relaxation. Genetically depleting FBXO42 or pharmacologically targeting its E3 ligase activity attenuates the Notch signaling-related leukemia development in vivo. Together, our findings not only revealed FBXO42 as a critical regulator of the Notch pathway by modulating RBPJ-dependent global chromatin landscape changes but also provided insights into the therapeutic intervention of the Notch pathway for leukemia treatment.

Figures
Products